PTC Chart

1 Month

	Date	Diff
	2025-05-02	+2.4 %
The PTC (PTC) stock rose 2.4% due to positive investor sentiment following a broader market uptrend and strong performance indicators such as growth in GST collections and bullish signals from key market indices. PTC Therapeutics' stock rose 2.4% following a report from Leerink Partners that significantly raised their earnings per share estimates for FY2026, indicating improved financial outlook for the company.
	2025-05-01	+0.88 %
PTC Inc. (NASDAQ:PTC) shares experienced a 2.84% increase, trading at $159.37, following a month of 6.58% growth, despite a year-over-year decline of 9.33%, likely indicating investor optimism about the stock's potential undervaluation. The increase in stock price may be influenced by positive market sentiment or favorable company news. PTC Therapeutics, Inc. (NASDAQ:PTCT) stock rose by 0.88% due to significant investments from several institutional investors, including Raymond James Financial Inc., which acquired a stake valued at approximately $2.2 million during the fourth quarter, signaling increased confidence in the company's potential.
	2025-04-29	+1.2 %
The article discusses GOP Senator Rand Paul's intention to introduce a resolution that could limit President Trump's authority on tariffs, leading to a potential conflict with the administration's stance on trade policies, while the PTC stock recently rose by 1.2%. PTC's stock may have gone up due to positive market sentiment about its business performance, potential new opportunities, or external factors such as favorable trade conditions, though the article does not provide specific reasons for PTC's stock increase.
	2025-04-28	-1.43 %
PTC (PTC) stock fell by 1.43% amid market reactions to various corporate developments, including news about management changes and strategic moves by other companies. The decline in PTC stock could be attributed to general market volatility or investor sentiment surrounding management transitions and competitive moves in the industry, leading to uncertainty regarding its future performance.
	2025-04-25	+1.58 %
PTC (NASDAQ:PTC) stock rose by 1.58% after Robert W. Baird raised its price target from $181 to $185, maintaining an outperform rating, amid mixed analyst ratings and price target adjustments from other firms. PTC (NASDAQ: PTC) stock rose 1.58% due to recent updates in price targets and ratings from analysts, as well as significant investments from institutional investors who have increased their holdings in the company.
	2025-04-24	+2.67 %
PTC (NASDAQ:PTC) stock rose by 2.67% due to strong institutional ownership and favorable analyst recommendations, suggesting positive long-term growth potential compared to competitors like Qualys (NASDAQ:QLYS). PTC Inc. (NASDAQ:PTC) stock rose by 2.67% due to a consensus "Moderate Buy" recommendation from analysts, who have adjusted their price targets upwards, indicating positive sentiment and confidence in the company's growth potential.
	2025-04-16	-2.09 %
PTC (NASDAQ:PTC) stock fell by 2.09% after Barclays lowered its price target from $215.00 to $175.00, indicating potential concerns among investors about the company's future performance.
	2025-04-15	+0.35 %
The article discusses the ongoing trade tensions between the U.S. and China, highlighting the potential for short-term damages to the U.S. economy from China's tariffs, but ultimately positing that China cannot win in the long-term and will eventually face significant losses. The PTC (PTC) stock likely rose by 0.35% due to investor sentiments influenced by the broader market expectations regarding U.S.-China trade relations, leading to optimism in the tech and manufacturing sectors, as these industries could see benefits from a resolution or improvement in trade conditions.
	2025-04-14	+0.84 %
PTC Therapeutics, Inc. (PTCT) stock saw a 0.84% increase due to significant institutional investment activity, including new positions and increased holdings by multiple hedge funds, alongside positive revisions in price targets and ratings from several research firms. PTC Inc. (NASDAQ:PTC) saw a 0.84% increase in its stock price due to various changes in institutional investor holdings, including significant increases from some firms, and overall positive analyst sentiment despite mixed ratings and price target adjustments.
	2025-04-10	-3.67 %
The article discusses the decline of PTC stock by 3.67% amid concerns over President Trump's tariffs and economic policies, particularly following his decision to pause tariffs on most countries except China. The stock's decline is attributed to investor fears regarding the potential economic impact of ongoing trade tensions and the lack of confidence in U.S. economic leadership.
	2025-04-09	+9.14 %
PTC Inc. (NASDAQ:PTC) experienced a 9.14% increase last night, despite a recent overall decline in its stock value over the past month and year, indicating possible renewed investor interest or optimism in the company's future prospects. The stock likely goes up due to positive market sentiment, potential financial developments, or investor speculation about the company's performance moving forward.
	2025-04-07	-0.06 %
The article discusses a Minnesota police chief's decision not to charge a woman who vandalized a Tesla, citing a compassionate approach after the victim only sought repair costs. The PTC stock may have gone down by -0.06% due to negative sentiment regarding incidents involving Tesla vehicles amidst broader scrutiny of Elon Musk and Tesla's public perception. The article discusses the controversial history and practices of Clearview AI, a facial recognition technology company founded by Hoan Ton-That, detailing its application in immigration enforcement and potential violations of privacy laws amid its ties to far-right ideologies, which ultimately reveal a dystopian perspective on surveillance. PTC (PTC) stock declined by 0.06% the previous night, potentially due to broader market fluctuations or investor reactions to news regarding its business practices or industry developments, although specific reasons for PTC stock's drop were not provided in the article. The article reports that PTC Inc. (NASDAQ: PTC) experienced a slight decline in its stock price, down 0.06%, attributed to a range of institutional investors modifying their stakes, including a significant decrease by CIBC Private Wealth Group LLC, and analysts adjusting their ratings, which may reflect investor sentiment regarding the company's recent earnings performance and market conditions.
	2025-04-04	-6.53 %
PTC Inc. (NASDAQ:PTC) stock dropped by -6.53% due to significant share sales by institutional investors, including JPMorgan Chase & Co. reducing its stake by 28.3%, along with recent insider selling, which may have triggered negative sentiment among investors.
	2025-04-02	+0.61 %
PTC Therapeutics, Inc. (NASDAQ:PTCT) experienced a 0.61% increase in stock price due to significant investments from institutional investors in the 4th quarter, indicating growing confidence in the company’s potential, despite some insider selling and mixed analyst ratings. PTC Therapeutics, Inc. (NASDAQ:PTCT) saw its stock rise by 0.61% despite an 8.8% drop earlier in the trading day due to a price target reduction from JPMorgan Chase & Co., while analysts have mixed ratings and price targets, with some indicating strong buy potential, contributing to the stock's eventual uptick.
	2025-04-01	+0.81 %
The article highlights the explosive growth in the tech industry fueled by AI investments, leading to significant wealth creation among tech moguls, which contributed to a 0.81% increase in PTC stock likely amid positive investor sentiment surrounding AI advancements and tech valuations. PTC (PTC) stock rose due to heightened investor excitement and optimism linked to the broader tech sector's growth driven by advancements in AI and substantial funding inflows. PTC Therapeutics (PTCT) stock increased by 0.81% as several analysts raised their price targets and ratings on the company, indicating positive sentiment despite JPMorgan's reduction of its price objective. PTC (PTC) stock was up 0.81%, likely due to positive market sentiment and investor analysis on its performance amidst broader market trends, though specific reasons for the increase are not detailed in the article.
	2025-03-31	+0.1 %
PTC Inc. (NASDAQ:PTC) saw a 0.1% increase in its stock, attributed to a mix of institutional investors adjusting their stakes, analysts upgrading their price targets, and a general positive outlook reflected in multiple buy ratings from equity research firms. PTC Inc. (NASDAQ:PTC) stock rose by 0.1% following significant increases in institutional investment, particularly a 79.8% stake increase from Korea Investment CORP, and favorable analyst ratings despite a recent earnings miss.
	2025-03-28	-3.44 %
PTC Therapeutics' stock (PTC) declined by 3.44% following the European Commission's decision to adopt a negative opinion from the Committee for Medicinal Products for Human Use regarding the renewal of authorization for its drug Translarna, impacting investor sentiment. The article discusses a significant premarket rise in U.S. Steel shares following reports of Nippon Steel's plans to invest heavily in the American company to gain approval for their merger, contrasting with the recent decline in PTC stock by -3.44%. The decline in PTC stock may be attributed to market reactions to broader industry news surrounding steel company transactions and potential regulatory impacts, which could create uncertainty for investors in related sectors. PTC Therapeutics, Inc. (NASDAQ:PTCT) stock fell by -3.44% last night, potentially influenced by insider selling and mixed analyst ratings. PTC Inc. (NASDAQ: PTC) stock fell by 3.44% largely due to a combination of recent insider selling by Director Corinna Lathan and the company missing earnings expectations in its latest quarterly report. PTC stock experienced a decline of 3.44% amidst broader market weakness, driven by concerns over earnings and volatility, compounded by significant foreign investor withdrawals.
	2025-03-27	-1.13 %
PTC Inc. (NASDAQ:PTC) stock was down 1.13% last night, primarily due to a recent decline in earnings that missed analyst expectations and insider selling, along with mixed institutional investment activity. PTC (NASDAQ:PTC) stock fell by 1.13% due to a combination of negative investor sentiment following a missed earnings estimate and insider selling activity, which may have raised concerns among shareholders.
	2025-03-25	+0.84 %
CIBC World Markets Corp and other institutional investors have recently increased their positions in PTC Therapeutics, contributing to a boost in the stock price by 0.84%, as positive investment sentiment is supported by analysts raising their target prices for the stock. The article reflects on the decline in quality and consistency of new streaming shows, highlighting a personal decision to avoid investing time in them due to the risk of disappointment and cancellation; it suggests that the streaming economics may contribute to this trend. PTC (PTC) stock recently went up by 0.84% likely due to positive market sentiment or company-specific developments that enhanced investor confidence.
	2025-03-24	+1.01 %
The article highlights a significant rise in defence sector stocks, with PTC and others benefiting from the Defence Acquisition Council's recent approvals for major capital acquisition proposals and favorable market conditions, which have boosted investor confidence. PTC stock went up because of the overall positive sentiment in the defence sector driven by increased military spending, acquisition reforms aimed at reducing order timelines, and a surge in demand for defence equipment in light of geopolitical developments.
	2025-03-21	-0.04 %
The article discusses Hawaiian Electric Industries' significant executive pay raises despite a challenging financial year marked by a $1.4 billion net loss and ongoing lawsuits related to the Lahaina wildfire, which included the company's settlement of $1.9 billion for its role in the disaster; this news contributes to the negative sentiment surrounding PTC stock, which was down 0.04%. The decline in PTC's stock could be attributed to concerns about executive compensation amidst poor financial performance, potential investor backlash due to ethical considerations regarding pay raises after substantial losses, and overarching uncertainties linked to the company's reputation and financial stability following the wildfire incident. PTC Therapeutics, Inc. (NASDAQ: PTCT) experienced a minor decline of 0.04% in stock price due to significant changes in hedge fund positions, with AlphaQuest LLC substantially reducing its holdings and analysts adjusting their ratings and price targets. The stock's decline can be attributed to negative sentiment from hedge funds, including AlphaQuest LLC's drastic reduction of its stake, along with analysts lowering their ratings, which collectively may have raised concerns among investors. PTC Therapeutics, Inc. (PTC) experienced a slight decline of 0.04% in stock value, potentially influenced by recent insider sales of shares by key executives, which often raises concerns among investors regarding the company's outlook.
	2025-03-20	-0.83 %
The PTC (PTC) stock fell by 0.83% last night, possibly due to market fluctuations or investor reactions to broader economic conditions and profitability expectations for tech companies like AMD, which also recently reported a decrease in its shares amid competitive pressures in the AI and GPU markets. PTC (PTC) stock decreased by 0.83% last night amid broader market volatility driven by economic uncertainty and cautious investor sentiment following the Federal Reserve's decision to maintain interest rates steady.
	2025-03-19	+0.76 %
Rand Worldwide's stock, PTC, saw a 0.76% increase, attributed to its superior dividend yield of 1.6% and a lower payout ratio compared to its industry rivals, suggesting stronger financial health and attractiveness to investors.
	2025-03-18	+0.77 %
The article discusses Rand Worldwide's performance compared to its peers, highlighting its lower volatility, better dividend yield, and strong insider ownership as key advantages, while also noting that the company trades at a higher price-to-earnings ratio despite lower revenue and earnings than competitors. PTC (PTC) stock may have increased by 0.77% due to the favorable comparison of Rand Worldwide's dividend yield and its strong institutional ownership, suggesting positive investor sentiment and confidence in long-term growth.
	2025-03-17	+1.92 %
PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a 1.92% increase in its stock price, supported by an overall positive outlook with an average brokerage recommendation of "Moderate Buy" and several analysts raising their price targets in recent reports. The stock's rise can be attributed to favorable analyst ratings and upgraded price targets from multiple brokerages, indicating confidence in the company's growth potential and overall market performance. PTC Therapeutics, Inc. (PTCT) stock rose by 1.92% due to increased investor interest and positive adjustments in target prices from several research analysts, indicating strong potential for growth in the biopharmaceutical sector. PTC (PTC) stock increased by 1.92% despite being downgraded to a "hold" rating by StockNews.com and facing mixed analyst opinions, likely due to recent upgrades in price targets from various firms and strong institutional investor support.
	2025-03-14	+1.63 %
PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a 1.63% increase in its stock price due to positive developments in investor sentiment, including increased holdings from major investors and favorable price target revisions from various equity research analysts, indicating strong market confidence in the company's future performance and potential growth. PTC stock rose by 1.63% amid increasing investor interest in artificial intelligence and positive performance reports from some enterprise companies that bolster confidence in the tech sector, despite broader concerns about the pace of AI profitability and mixed earnings results elsewhere.
	2025-03-12	-0.18 %
PTC Therapeutics (PTCT) stock experienced a slight decline of 0.18% following a series of mixed ratings from various brokerages, despite Bank of America's upgrade of the stock to a neutral rating with an increased price target. The downturn can be attributed to profit-taking activities by insiders and a fluctuating analyst sentiment regarding the stock's future performance. PTC (PTC) stock experienced a decline of -0.18% amidst a turbulent political and economic landscape, primarily driven by fears of a potential recession tied to President Trump's unpredictable trade policies and their implications for economic stability. PTC stock experienced a slight decline of -0.18% amidst news that TSMC is planning to create a joint venture with U.S. chip designers to take over half of Intel's foundry division, which indicates ongoing struggles for Intel in the competitive chip market.
	2025-03-11	-2.32 %
PTC (NASDAQ:PTC) stock fell by 2.32% last night, despite having a strong historical performance with an average annual return of 16.42% over the past decade. The decline may arise from market fluctuations or investor sentiment but specific reasons for the decrease were not detailed in the article. Rand Worldwide's stock (PTC) decreased by 2.32% last night, potentially reflecting its higher price-to-earnings ratio compared to competitors and overall lower market confidence given its limited institutional investor ownership. PTC Inc. (NASDAQ:PTC) stock dropped by 2.32% due to a recent quarterly earnings report that showed earnings per share miss the consensus estimate by $0.12, which likely raised concerns among investors about the company's financial performance.
	2025-03-10	-1 %
PTC Therapeutics (PTCT) stock dropped 1.0% despite multiple analysts issuing bullish ratings and raising price targets, likely due to insider stock sales and general market sentiment impacting investor confidence. PTC Therapeutics (NASDAQ: PTCT) stock decreased by 1.0% amidst mixed analyst ratings and multiple insider stock sales, indicating some investor uncertainty. The price drop could be attributed to factors such as the initiation of coverage with a sector perform rating by Scotiabank and recent insider selling, which may signal lack of confidence among executives. PTC (PTC) stock experienced a decline of 1.0% despite an upgraded buy rating from StockNews.com and several analysts raising their target prices due to disappointing quarterly earnings that fell short of analyst expectations.
	2025-03-07	+1.3 %
PTC Therapeutics (PTC) stock rose by 1.3% following an upward revision of the company's FY2025 earnings per share estimates by Cantor Fitzgerald, as well as positive ratings from other analysts, indicating increased investor confidence. Walgreens' stock increased due to a buyout deal with private equity firm Sycamore Partners, which offered $11.45 per share, an approximately 8% premium, and a potential future payout linked to the sale of its primary-care businesses. The stock price rose because the buyout provides immediate value to shareholders and restores investor confidence amid Walgreens' ongoing financial struggles, while Sycamore's involvement is seen as a step towards a turnaround for the beleaguered drugstore chain.
	2025-03-06	-0.37 %
PTC Inc. (NASDAQ:PTC) stock declined by 0.37%, likely due to a significant increase in short interest and disappointing quarterly earnings results where the company missed analysts' expectations.
	2025-03-05	+1.72 %
PTC stock rose by 1.72% due to a positive sentiment in the market following value buying in utility and power shares, as well as a strong overall trend in global markets that helped lift the BSE Sensex by 740.30 points.
	2025-03-04	-1.32 %
The PTC stock fell by 1.32% due to concerns about increasing competitiveness from cheaper imported solar panels in Europe and a lack of strong government policies to support local manufacturers, mainly highlighted by companies like Meyer Burger relocating to the U.S. for better incentives. PTC Therapeutics, Inc. (NASDAQ: PTCT) saw a decline of 1.32% in its stock due to lowered earnings per share (EPS) estimates from analysts, with forecasts indicating continued losses and mixed reviews from various research firms affecting investor sentiment.
	2025-02-28	+0.54 %
The PTC (PTC) stock saw a 0.54% increase due to positive market trends influenced by ongoing developments in renewable energy and the growing demand for high-tech materials, particularly rare earth elements which are vital for new technologies.
	2025-02-27	-0.17 %
PTC (PTC) stock experienced a decline of -0.17% last night, partly due to ongoing protests and negative sentiment around CEO Elon Musk's controversial actions and comments, which have spurred a movement advocating for divestment from Tesla and criticism of its inflated stock valuation. The PTC stock decreased by 0.17% as uncertainty in U.S. energy policy, including the recent suspension of funding from the Inflation Reduction Act and shifts towards fossil fuels over renewables, adversely impacted investor sentiment.
	2025-02-26	+0.19 %
PTC Inc. (NASDAQ:PTC) stock rose by 0.19% following significant increases in institutional ownership, as multiple hedge funds, including Allworth Financial LP, raised their stakes in the company, indicating strong investor confidence amidst mixed earnings reports and market analyst ratings.
	2025-02-25	+0.09 %
PTC Inc. (NASDAQ:PTC) stock rose by 0.09% due to favorable adjustments in institutional investments, with various hedge funds increasing their stakes, despite a recent earnings miss. PTC Therapeutics, Inc. (NASDAQ: PTCT) saw a 0.09% increase in stock value, attributed to recent institutional investments and positive adjustments in price targets from several financial analysts following research reports boosting the company's outlook.
	2025-02-21	-2.48 %
PTC (PTC) stock fell by 2.48% due to market reactions surrounding NHPC's clarification regarding its potential acquisition of PTC shares, indicating that discussions are still in very early stages, which may have led to investor uncertainty. PTC (NASDAQ:PTC) stock dropped by 2.48% despite being upgraded to a "buy" rating by analysts due to disappointing quarterly earnings that missed analysts' expectations. PTC (PTC) stock fell by 2.48% amid a broader market decline influenced by foreign fund outflows, weak US markets, and a bearish sentiment in the Indian equity indices. PTC Therapeutics (NASDAQ:PTCT) stock fell by 2.48% as it approaches its upcoming quarterly earnings report amid mixed analyst ratings and insider stock sales, contributing to investor concerns.
	2025-02-20	-2.45 %
PTC Therapeutics (NASDAQ:PTCT) stock fell by 2.45% despite recent price target increases from several analysts, particularly due to insider selling and mixed analyst ratings, leading to investor caution. PTC Therapeutics, Inc. (NASDAQ: PTCT) stock fell by 2.45% likely due to mixed ratings from analysts, insider selling, and a general market reaction to recent investments and evaluations by large funds, creating uncertainty among investors.
	2025-02-18	-0.18 %
PTC Therapeutics (NASDAQ:PTCT) stock fell by 0.18% after StockNews.com downgraded it from a buy rating to a hold rating, indicating a more cautious outlook amidst mixed sentiments from other analysts. PTC Inc. (NASDAQ:PTC) stock declined by 0.18% as the New Mexico Educational Retirement Board reduced its holdings and the company reported lower-than-expected quarterly earnings, missing analysts' estimates.
	2025-02-14	+1.89 %
PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a 1.89% increase in its stock price, attributed in part to positive analyst ratings and price target upgrades from several equity research firms, alongside increased investor interest and institutional buying activity. The article notes that PTC (PTC) stock increased by 1.89% last night, likely due to overall positive market sentiment driven by optimism surrounding US-China trade negotiations and favorable inflation data, which may suggest a more stable economic environment.
	2025-02-13	+0.82 %
The PTC stock rose by 0.82% due to overall positive market momentum and specific developments in the sector that might have lifted investor sentiment, despite various companies reporting mixed financial outcomes. PTC (NASDAQ:PTC) stock saw a 0.82% increase, despite being downgraded by StockNews.com from a "buy" to a "hold" rating, likely due to positive price target upgrades from other analysts and strong Institutional investor interest, indicating confidence in the company's future performance.
	2025-02-12	-0.84 %
PTC (PTC) stock experienced a decline of 0.84% due to broader market volatility and concerns over macroeconomic conditions, which were exacerbated by rising inflation and tariff tensions impacting investor sentiment. PTC stock declined by 0.84% last night, reflecting broader market concerns influenced by trade tensions and volatility affecting investor sentiment.
	2025-02-11	-0.26 %
PTC Inc. (PTC) stock declined by 0.26% after it reported earnings for the quarter that missed analysts’ expectations, with earnings per share of $0.79 compared to the anticipated $0.91. PTC Inc. (NASDAQ: PTC) stock experienced a decline of 0.26% after missing earnings expectations in its latest report, which likely raised concerns among investors about the company's short-term performance.
	2025-02-10	-0.35 %
PTC Inc. (NASDAQ:PTC) stock fell by 0.35% due to a mix of selling pressure by institutional investors, concerns over a missed earnings estimate, and analysts lowering their price targets for the stock.
	2025-02-07	-1.51 %
PTC Inc. (NASDAQ:PTC) stock declined by 1.51% primarily due to abrdn plc reducing its stake by 9.3% and the company reporting earnings that missed analysts' expectations, which led to concerns about its current performance. PTC (NASDAQ:PTC) stock fell by 1.51% after Citigroup reduced its price target from $200.00 to $195.00 and assigned a "neutral" rating, which reflects a more cautious outlook on the company's performance, compounded by a recent earnings miss. PTC Therapeutics, Inc. (NASDAQ:PTCT) stock fell by 1.51% following an update from Cantor Fitzgerald, which lowered its FY2025 earnings per share estimates from ($2.84) to ($3.26), contributing to investor concerns about the company's financial outlook. PTC Therapeutics (PTCT) stock decreased by 1.51% following the company's recent earnings report that revealed a loss, despite beating analysts' expectations, as well as notable insider sales and mixed analyst ratings. The decline may be attributed to profit-taking by investors after positive earnings news, increasing concerns over the company's financial health given its negative earnings per share, and ongoing market volatility. PTC Inc. (NASDAQ:PTC) stock declined by 1.51% following the company's fourth-quarter earnings report, which revealed earnings per share of $0.79, missing the consensus estimate of $0.91 by $0.12, indicating weaker financial performance than analysts expected.
	2025-02-06	-9.56 %
PTC (NASDAQ: PTC) stock declined by 8.8% following a disappointing first-quarter 2025 earnings report that did not meet investor expectations.
	2025-02-05	-0.69 %
Shares of PTC Therapeutics, Inc. (PTCT) recently saw a slight decline of 0.69% to close at $48.70 despite a prior surge following a raised price target from Cantor Fitzgerald, likely influenced by insider stock sales and fluctuations in trading volume.
	2025-02-04	+0.63 %
PTC Inc. (NASDAQ:PTC) experienced a 0.63% increase in stock value due to significant institutional investment activity, including a 44.3% increase in holdings by Blue Trust Inc. and several other funds adjusting their positions, which reflects growing confidence in the company's prospects.
	2025-01-29	-0.97 %
The article highlights the stability and resilience of the US stock market while focusing on Union Pacific Corporation (NYSE:UNP) as a long-term safe stock investment, noting its impressive dividend growth and operational advancements. PTC (Positive Train Control) stock may have declined by -0.97% due to typical market volatility or specific factors affecting the railroad sector, but the article does not explicitly mention the reasons for the stock's decline. PTC stock dropped by 0.97% last night, possibly due to broader market fluctuations and investor reactions to upcoming fiscal policies expected in the Union Budget, impacting overall market sentiment.
	2025-01-27	-0.25 %
The article compares Adlai Nortye and Ionis Pharmaceuticals, highlighting that while Adlai Nortye has a stronger consensus rating and higher potential upside, it also has lower institutional ownership compared to Ionis. PTC (PTC) stock's decline of -0.25% could be attributed to recent market fluctuations, investor sentiment or specific factors affecting the biotechnology sector, but the article does not provide detailed reasons for PTC's stock movement specifically. PTC (NASDAQ:PTC) stock declined by 0.25% ahead of its upcoming quarterly earnings report, primarily due to recent insider selling of shares and mixed analyst ratings that may have raised concerns among investors.
	2025-01-24	-0.06 %
PTC Therapeutics (NASDAQ:PTCT) stock fell by 0.06% due to a mixed outlook on earnings revisions, with analysts adjusting future EPS estimates, as well as insider selling, which may have raised concerns among investors. The article discusses a significant increase in retail store closures in 2024, with 7,325 closures attributed to inflation and a shift towards online shopping, which has negatively impacted physical retailers like PTC (PTC) stocks, causing a decline of -0.06%. PTC stock likely went down due to the broader trend of increasing retail disruptions and store closures, leading to increased market uncertainty about the future of traditional retailers. PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a slight decline of -0.06% in its stock price following analysts' lowered earnings estimates for FY2025 and mixed ratings from various financial institutions, indicating uncertainty about the company's future performance despite some positive quarterly earnings results.
	2025-01-23	+0.61 %
PTC Inc. (NASDAQ:PTC) stock increased by 0.61% due to overall positive investor sentiment and recent upgrades from multiple analysts, indicating a strong buy recommendation and increased price targets for the stock.
	2025-01-22	+0.02 %
PTC Inc. (NASDAQ:PTC) saw a slight increase of 0.02% in its stock price due to significant buying activity from institutional investors, including Diversify Wealth Management LLC and others, which has contributed to a stronger outlook and a consensus rating of "Moderate Buy" among analysts. The article discusses the innovative journey of creating a custom laptop from scratch, showcasing various technical challenges and achievements, culminating in a functional, open-source device; the PTC stock increased by 0.02% due to positive investor sentiment surrounding technological innovation and growth in the values associated with companies focused on advanced engineering and hardware development. The PTC stock saw a slight increase of 0.02% as part of a broader trend of rising IT stocks, which contributed to the overall positive sentiment in the market despite declines in smaller-cap stocks. PTC Industries' stock rose by 0.02% as the company is poised to benefit from global titanium supply disruptions due to sanctions on Russia, bolstering its production capabilities with the recent commissioning of a VAR furnace dedicated to aerospace-grade titanium alloy manufacturing.
	2025-01-21	+0.06 %
PTC (NASDAQ:PTC) stock rose by 0.06% as it continues to show strong revenue and earnings compared to Informatica, along with a lower price-to-earnings ratio indicating better affordability, despite analysts favoring Informatica for higher potential upside.
	2025-01-17	+0.44 %
PTC Inc. (NASDAQ:PTC) stock rose 0.44% likely due to increased institutional investment and positive analyst upgrades, indicating growing confidence in the company's performance and future prospects.
	2025-01-15	-0.07 %
PTC Inc. (NASDAQ:PTC) experienced a slight decline of 0.07% in its stock price, which may be attributed to recent insider selling, as significant shares were sold by company executives, indicating potential concerns about stock performance or profitability among insiders.
	2025-01-14	+1.69 %
PTC Inc. (NASDAQ:PTC) stock rose by 1.69% due to positive analyst ratings and upgrades from various research firms, suggesting strong investment potential and an optimistic outlook for the company.
	2025-01-13	+0.02 %
PTC Therapeutics, Inc. (NASDAQ:PTCT) experienced a slight increase of 0.02% in its stock price, attributed to positive analyst ratings and upgrades from firms like Royal Bank of Canada and Morgan Stanley, which boosted investors' confidence in the company's prospects. The Supreme Court's refusal to block climate change lawsuits from states against major oil companies has sparked concerns in the fossil fuel industry, contributing to a slight increase in PTC stock by 0.02%. The stock rose likely because investors reacted positively to the potential for renewable energy initiatives gaining traction in response to increased legal pressure on oil companies regarding climate issues. PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a slight increase of 0.02% in its stock price, influenced by recent transactions by large investors and positive analyst ratings that have elevated their price targets for the stock. The stock's rise can be attributed to increased investor interest and positive upgrades from several brokerages, suggesting a favorable outlook on the company's growth and future performance in the biopharmaceutical sector. PTC Therapeutics, Inc. (NASDAQ:PTCT) saw a 0.02% increase in its stock price following a series of positive analyst ratings upgrades and increased hedge fund investments, reflecting growing confidence in the company's growth potential. The article reports that the PTC (PTC) stock rose by 0.02% amid a significant setback to the oil industry as the Supreme Court allowed lawsuits from California and other states to proceed, holding major oil companies accountable for climate change damages. The stock likely increased due to market reactions to the Supreme Court's decision, signaling potential profitability for companies focused on alternative energy solutions as fossil fuel companies face legal challenges.
	2025-01-08	+0.69 %
PTC Inc. (NASDAQ:PTC) stock rose by 0.69% due in part to positive activity from institutional investors, including increased holdings by Nordea Investment Management and significant purchases by other funds, alongside favorable analyst ratings, including price target upgrades.
	2025-01-03	+0.84 %
PTC (NASDAQ: PTC) stock rose 0.84% due to strong institutional ownership, higher revenue, and earnings compared to its competitor WaveDancer, along with favorable analyst recommendations suggesting a potential upside in its stock price.
	2024-12-24	+1 %
The article discusses a historical parallel between irrational market behaviors, such as the tulip craze of the 17th century, while touching on societal issues surrounding transgender treatments. Regarding the increase in PTC (PTC) stock, the text does not specifically address the reasons for its 1.0% rise, leaving the cause unspecified.
	2024-12-23	-1.24 %
PTC Inc. (NASDAQ:PTC) shares fell by 1.24% despite a "Moderate Buy" consensus rating from analysts, influenced by insider selling activity that raised concerns about the stock's future performance. The article discusses Enlight Renewable Energy Ltd.'s announcement of a $550 million debt financing package for its Roadrunner solar and energy storage project in Arizona, expected to reach full operation by the end of 2025. PTC (PTC) stock is likely down -1.24% due to investor reactions to broader market trends, potential concerns about the project's completion timeline, or financial specifics that may have prompted reassessment of the company's outlook. PTC Inc. (NASDAQ: PTC) stock fell by 1.24% recently, influenced in part by insider selling, as well as varying ratings and price target adjustments from several research firms, which may have created downward pressure on the stock.
	2024-12-20	+0.24 %
PTC Therapeutics (NASDAQ:PTCT) stock experienced a slight increase of 0.24% amidst mixed analyst ratings, with price targets raised by several firms, indicating a generally optimistic outlook despite a downgrade to a "hold" rating by StockNews.com. The stock's rise can be attributed to the positive adjustments in target prices and ratings from major equity analysts, suggesting confidence in the company's future performance.
	2024-12-17	-1.58 %
PTC Inc. (NASDAQ:PTC) stock decreased by 1.58% as several institutional investors modified their holdings, and insider selling could have contributed to market sentiment.
	2024-12-16	+0.7 %
PTC Therapeutics, Inc. (NASDAQ:PTCT) saw its stock rise 0.7% after State Street Corp increased its stake by 5.4% in the third quarter, reflecting positive sentiment and investment activity from institutional investors, which may boost investor confidence and demand for the stock. PTC Therapeutics (NASDAQ: PTCT) stock rose by 0.7% following an upgrade from Morgan Stanley, which changed its rating from equal weight to overweight and raised the price target from $45.00 to $67.00, indicating positive sentiment among analysts regarding the company’s future performance.
	2024-12-13	-1.3 %
PTC (PTC) stock experienced a decline of 1.3% due to concerns over overvaluation relative to global peers and disappointing corporate earnings, which have been exacerbated by foreign institutional investor sell-offs and ongoing inflation worries in India. The PTC (PTC) stock experienced a decline of 1.3% due to recent regulatory developments involving former Chairman Rajib Kumar Mishra, who faced a penalty and restrictions imposed by SEBI, affecting investor sentiment. PTC (PTC) stock fell by 1.3%, as the market reacts to mixed sentiments surrounding the potential for cryptocurrency regulation and Trump’s pro-crypto administration, amidst concerns over wealth inequality and crypto-related fraud.
	2024-12-12	-0.29 %
PTC Inc. (NASDAQ:PTC) stock experienced a decline of 0.29% due to recent insider selling, where key executives reduced their holdings, alongside mixed analyst ratings that may have affected investor confidence.
	2024-12-09	-0.66 %
PTC Therapeutics, Inc. (PTCT) shares dropped by 0.66%, reflecting mixed analyst recommendations and insider selling, which may indicate concerns over the stock's performance despite some price target increases from brokerages.
	2024-12-06	+0.03 %
PTC Therapeutics (PTCT) stock rose by 0.03% following Citigroup's increase of its price target from $26.00 to $32.00, despite maintaining a "sell" rating, indicating some investor confidence in the company amid mixed analyst ratings. PTC Therapeutics (NASDAQ:PTCT) stock increased by 0.03% following an upgrade from StockNews.com from a "hold" to a "buy" rating, alongside several other analysts raising their price targets on the stock, which indicates positive expectations from investors. PTC Therapeutics (NASDAQ: PTCT) shares increased by 0.03% despite insider selling activities and a previous gap down, largely due to multiple analysts upgrading their ratings and price targets for the stock, signaling positive market sentiment. PTC Therapeutics (PTCT) stock saw a 0.03% increase following a series of positive analyst upgrades that raised its price targets, with Barclays, Robert W. Baird, and Royal Bank of Canada among those boosting their price objectives and ratings. PTC Therapeutics, Inc. (PTCT) stock increased by 0.03% following a combination of slightly lowered earnings estimates from analysts and several bullish revisions of price targets by other research firms, reflecting a mixed sentiment among investors.
	2024-12-05	-0.16 %
PTC Therapeutics, Inc. (NASDAQ:PTCT) stock experienced a slight decline of 0.16% despite hitting a 52-week high earlier in the trading session, primarily influenced by significant insider selling, which raised concerns among investors and may have contributed to the stock's downward movement. PTC Inc. (PTC) stock fell by 0.16% after Glenmede Trust Co. NA reduced its holdings in the company by 11.1%, alongside insider selling and varying institutional investments, indicating potential uncertainty about the stock's short-term prospects. PTC Therapeutics (PTCT) stock experienced a minor decline of -0.16% despite positive upgrades from research firms, primarily due to insider selling, with significant shares sold by executives, which could raise concerns about the company's future performance. PTC Therapeutics (PTCT) stock is down by 0.16% despite recent upgrades in price targets from multiple analysts, likely influenced by significant insider selling, which may raise concerns about the company's future performance.
	2024-12-03	+0.41 %
PTC Inc. (NASDAQ:PTC) shares rose by 0.41% last night, likely due to a mix of institutional investment activity, positive analyst ratings, and the company's strong market position in software solutions for product development and the Industrial Internet of Things. PTC Inc. (NASDAQ: PTC) experienced a 0.41% increase in stock price, largely attributed to significant investment activity from institutional investors and hedge funds, as well as positive analyst ratings that reflect confidence in the company's performance. PTC Inc. (NASDAQ:PTC) saw a 0.41% increase in its stock price as several institutional investors adjusted their positions during the third quarter, indicating strong interest and confidence in the company's growth potential amidst positive analyst ratings and target price adjustments. PTC (NASDAQ:PTC) stock rose by 0.41% following JPMorgan Chase & Co.’s upgrade of its price target from $200.00 to $210.00 and their overweight rating on the technology company's stock, reflecting positive sentiment from various analysts. The article discusses the significant rise in shares of Janux Therapeutics following promising results from its experimental prostate cancer treatment, with stock climbing nearly 49% due to exceeding investor expectations and positive clinical outcomes. PTC stock likely went up as a reaction to the broader optimism in the biotechnology sector, driven by Janux's successful trial results and advancements in cancer treatment showcasing market potential.
	2024-12-02	-0.34 %
PTC Therapeutics (PTCT) stock fell by 0.34% following a significant licensing deal worth up to $2.9 billion for its Huntington's treatment, as investors took profits after an initial surge. The decline may be attributed to profit-taking after the stock's previous gains in response to the announcement of the licensing deal.
	2024-11-27	-0.13 %
The article discusses the involvement of Elon Musk's social platform, X, in the bankruptcy sale of Alex Jones's Infowars, highlighting X's objection to the sale of Jones's accounts due to its terms of service. PTC (PTC) stock decreased by 0.13% possibly due to market reactions to related legal and financial issues involving high-profile figures, impacting investor sentiment. PTC Therapeutics (PTCT) stock decreased by 0.13% despite receiving a price target increase from Wells Fargo & Company, as mixed ratings from various analysts, including a downgrade to "hold" by StockNews.com, may have contributed to investor uncertainty and selling pressure.
	2024-11-26	-0.66 %
The article discusses challenges faced by Austin, Texas, in implementing a fully electric bus system, where the newly purchased buses will remain idle for over a year due to inadequate charging infrastructure and issues with a bankrupt manufacturer, Proterra. The decline in PTC stock, noted to be down by 0.66%, could be attributed to these operational challenges and uncertainties related to the electric bus transition, as well as concerns over the reliability and availability of parts from a bankrupt supplier.
	2024-11-22	+2.54 %
PTC Inc. (PTC) stock rose by 2.54% following positive adjustments in target prices and ratings from multiple equity analysts, indicating strong investor confidence amidst institutional trading activity.
	2024-11-21	+2.25 %
The article discusses the increasing trend of regional investment cooperation among Central Asian countries, particularly highlighted by a meeting between the presidents of Uzbekistan and Kazakhstan that announced plans for significant bilateral projects, which contributed to PTC (PTC) stock rising by 2.25%. The rise in PTC (PTC) stock can be attributed to the positive outlook generated by these bilateral initiatives, particularly the establishment of a logistics hub and the growing regional collaboration in energy and industrial projects, indicating strong economic growth potential in Central Asia. PTC (NASDAQ: PTC) stock increased by 2.25% due to the company's strong positioning in the manufacturing industry's shift towards digital technology and industrial software that integrates digital and physical environments, suggesting promising growth ahead.
	2024-11-20	-0.41 %
The article compares Qualigen Therapeutics and Ionis Pharmaceuticals, highlighting that Ionis is perceived as a superior investment due to significantly higher institutional ownership, a more favorable consensus rating, and greater potential upside. PTC (PTC) stock's decline of -0.41% is not directly addressed in the article, but it may be influenced by broader market trends or sector performance in biotechnology.
	2024-11-19	+0.01 %
PTC Inc. (NASDAQ: PTC) stock increased by 0.01% as CIBC Asset Management and other institutional investors significantly raised their positions in the company, reflecting growing confidence and investment interest in the stock.
	2024-11-18	-0.39 %
PTC (PTC) stock was down by 0.39% as a result of overall market declines driven by foreign fund outflows, selling in IT stocks, and negative influences from weak US market leads. Spirit Airlines has filed for Chapter 11 bankruptcy protection due to ongoing financial struggles, including losses and a failed merger, leading to a significant drop in its stock price from $3.22 to $1.07 after the announcement. The decline in Spirit Airlines' (PTC) stock is primarily attributed to the company's financial difficulties and the announcement of its bankruptcy filing, which raised concerns among investors about its stability and future operations. The article reports that PTC (PTC) stock experienced a decline of 0.39% last night. The reasons for the drop in PTC stock can vary, but they may include market fluctuations, negative investor sentiment, disappointing earnings, or broader economic concerns.
	2024-11-15	-0.58 %
The PTC Therapeutics (PTCT) stock declined by 0.58% following various institutional investments and mixed analyst ratings, suggesting cautious sentiment among investors despite some upgrades to buy ratings. The stock may have gone down due to a combination of analyst ratings indicating uncertainty (with three analysts having sell ratings) and market reactions to recent trading activity by large investors. The article mentions that PTC stock decreased by 0.58%, although it does not provide specific reasons for this decline. Potential reasons for stock fluctuations can include market trends, investor sentiment, or company-specific news, but none are detailed in the provided text.
	2024-11-14	-1.21 %
PTC (Plug Power, Inc.) stock declined -1.21% due to weak third-quarter earnings that missed revenue expectations, lowered full-year revenue guidance for 2024, and analysts revising price targets downwards amidst concerns about high cash burn and unclear market conditions in the hydrogen sector. PTC (PTC) stock experienced a decline of -1.21% as part of a broader market reaction to a significant day of earnings announcements from over 1,181 companies, where investors are closely monitoring key sectors for financial performance amid ongoing economic shifts. The article discusses the recent decline of PTC (PTC) stock, which fell by -1.21%, while also featuring an interview with Doug Casey about the potential implications of Donald Trump's second term for the economy and stock market. The stock's decline can be attributed to broader market trends, economic uncertainties, and investor reactions to Trump's policies, which may lead to inflation and increased government spending rather than sound economic fundamentals. PTC Inc. (NASDAQ:PTC) stock fell by 1.21% after Crossmark Global Holdings Inc. reduced its position in the company by 5.2%, indicating a potential decrease in investor confidence, amidst mixed ratings and target price adjustments from various analysts.
	2024-11-13	+0.28 %
The article discusses the overall decline in Indian stock markets amid rising inflation, sustained foreign investor outflows, and poor corporate earnings, while mentioning that PTC (PTC) stock rose by 0.28% possibly due to investor interest in specific sectors or stocks perceived to be resilient despite the broader market downturn. PTC India recently reported mixed Q2 financial results, showing a year-over-year revenue decline but a profit increase, which positively impacted its stock performance, leading to a 0.28% rise despite an overall cautious outlook from analysts. The stock's increase is attributed to improved profitability and effective cost management, despite concerns over declining revenues and earnings per share.
	2024-11-11	+0.65 %
PTC stock rose by 0.65% as U.S. policymakers continue to support Intel's efforts to maintain domestic semiconductor manufacturing, despite Intel's ongoing challenges and significant losses this year.
	2024-11-06	+4.24 %
PTC stock rose by 4.24% due to positive market sentiment following Donald Trump's election win, which is anticipated to increase government spending in sectors such as defense and energy, thus benefiting related companies and boosting investor confidence. The PTC stock rose by 4.24% due to positive market sentiment following Donald Trump's election victory, which is expected to boost defense spending and other sectors, attracting investor interest.
	2024-11-05	+2.02 %
PTC Therapeutics, Inc. (NASDAQ: PTCT) saw a 2.02% increase in stock price last night, driven by significant investment increases from institutional investors, including a notable 21.5% boost in shares by Mirae Asset Global Investments, indicating growing confidence in the company's potential despite recent earnings misses.

1
500 / page